News

Shire presented new data on its approved therapy Natpara for the treatment of patients with chronic hypoparathyroidism at ENDO 2018, the Endocrine Society’s 100th Annual Meeting and Exposition held March 17-20 in Chicago. Natpara is a recombinant human parathyroid hormone (rhPTH) that’s designed to replace the natural hormone, called PTH,…

TransCon PTH, an investigational therapy for hypoparathyroidism (HP) being developed by Ascendis Pharma, showed positive results in healthy volunteers, according to initial data from a Phase 1 clinical trial. The company presented the trial data recently at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California. “We look forward to…

Shire plans a Phase 4 clinical trial of its parathyroid hormone therapy Natpara as an add-on to standard hypothyroidism treatment. Hypoparathyroidism is caused by abnormal low levels of parathyroid hormone (PTH), which regulates levels of calcium in blood and bones. Low levels of the hormone lead to a  mineral imbalance that…

Treatment of patients with pseudohypoparathyroidism type 1B should involve lowering parathyroid hormone levels to avoid adverse effects on bone, according to a recent study. Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterized by normal renal function and resistance to the action of the parathyroid hormone — a hormone…

Hypoparathyroidism may lead to the development of a rare neurological disorder manifesting with seizures, a case study reveals. The study, “A Case of Seizure Revealing Fahr’s Syndrome with Primary Hypoparathyroidism,” was published in the American Journal of Case Reports. The patient, a 52-year-old man, was admitted…

Emergency cards can help ease the diagnosis and treatment of an acute crisis of low or high blood calcium levels among patients with…